Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Apimeds Pharmaceuticals US, Inc (APUS)
USD0.73
0.00 (-0.34%)
US AMEX Healthcare Drug Manufacturers - Specialty & Generic
Address
2 East Broad Street 8525
Hopewell, NJ, US
Hopewell, NJ, US
CEO
Vinod Menon
Website
apimedsus.com
IPO
2025-05-09
CIK 1894525 ISIN US03771D1028
Description
Apimeds Pharmaceuticals US, Inc. (APUS) functions as a clinical-stage biopharmaceutical firm operating within the United States. This company is dedicated to the entire lifecycle of its flagship product, Apitox – from its initial investigation and development to its production, market introduction, and sales. Apitox, a key active pharmaceutical ingredient, is specifically designed to alleviate inflammation and manage pain symptoms experienced by individuals suffering from osteoarthritis and multiple sclerosis. Established in 2020, APUS has its corporate headquarters situated in Hopewell, New Jersey, and operates as a subsidiary of Api Meds, Inc.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.73
0.00 (-0.34%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
144.1K
Beta
-1.03
Float Shares
226.5K
Free Float %
18.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.33% | -5.33% | -24.47% | +4.41% | -35.16% | -13.41% | -21.11% | -35.45% | -35.45% | -35.45% | -35.45% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.73
Quality scores
Altman Z-Score
-0.80
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%—
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+50.0% ★ Q1'26: -549.4% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%—
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%—
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-7.6% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+757.3% Q1'26: +1,240.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.65× Q1'26: -0.20× (vs Q1'25)
Valuation Multiples
From
To
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
6
Total invested
803.0K
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
6
-1 vs prev Q
New positions
3
Closed positions
4
Increased
5
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | HEMENWAY TRUST CO LLC | 274.0K +— (+0.0%) | 490.3K +40.9K (+9.1%) | 2.52% +2.266 pp | 0.04% +0.005 pp | USD1.79 +0.0% | 3 qtrs — |
| 2 | — | 95.9K +95.9K (+100.0%) | 171.6K +171.6K (+100.0%) | 0.88% +0.882 pp | 0.00% +0.000 pp | USD1.79 +0.0% | 1 qtrs NEW |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 40.1K +5.2K (+14.8%) | 71.7K +14.5K (+25.3%) | 0.37% +0.336 pp | 0.00% +0.000 pp | USD1.79 +0.0% | 3 qtrs — |
| 4 | VANGUARD FIDUCIARY TRUST CO | 24.0K +24.0K (+100.0%) | 43.0K +43.0K (+100.0%) | 0.22% +0.221 pp | 0.00% +0.000 pp | USD1.79 +0.0% | 1 qtrs NEW |
| 5 | TWO SIGMA SECURITIES, LLC | 10.6K +10.6K (+100.0%) | 18.9K +18.9K (+100.0%) | 0.10% +0.097 pp | 0.00% +0.002 pp | USD1.79 +0.0% | 1 qtrs NEW |
| 6 | UBS GROUP AG | 4.2K +3.6K (+619.4%) | 7.5K +6.5K (+685.2%) | 0.04% +0.038 pp | 0.00% +0.000 pp | USD1.79 +0.0% | 2 qtrs — |
| 7 | TOWER RESEARCH CAPITAL LLC (TRC) | — -10.0 (-100.0%) | — -16.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 8 | JANE STREET GROUP, LLC | — -27.2K (-100.0%) | — -44.6K (-100.0%) | 0.00% -0.025 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 9 | BANK OF AMERICA CORP /DE/ | — -40.0 (-100.0%) | — -66.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 71.1K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
12
Sells
0
Shares acquired
283.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+283,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-11 | Yoon Hankil | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 2.67 | 26.7K | 10,000 | D | ↗ |
| 2025-11-11 | Weintraub Bennett | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 2.67 | 26.7K | 10,000 | D | ↗ |
| 2025-11-11 | O'DONNELL CAROL A | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 2.67 | 26.7K | 10,000 | D | ↗ |
| 2025-11-11 | Koo Jakap | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 2.67 | 26.7K | 10,000 | D | ↗ |
| 2025-11-11 | Kogan Elona | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 2.67 | 26.7K | 10,000 | D | ↗ |
| 2025-10-15 | Yoon Hankil | Director | A-Award | A | Stock Option (right to buy) | 3,000 | 1.92 | 5.8K | 3,000 | D | ↗ |
| 2025-10-15 | Weintraub Bennett | Director | A-Award | A | Stock Option (right to buy) | 3,000 | 1.92 | 5.8K | 3,000 | D | ↗ |
| 2025-10-15 | O'DONNELL CAROL A | Director | A-Award | A | Stock Option (right to buy) | 3,000 | 1.92 | 5.8K | 3,000 | D | ↗ |
| 2025-10-15 | Koo Jakap | Director | A-Award | A | Stock Option (right to buy) | 3,000 | 1.92 | 5.8K | 3,000 | D | ↗ |
| 2025-10-15 | Kogan Elona | Director | A-Award | A | Stock Option (right to buy) | 3,000 | 1.92 | 5.8K | 3,000 | D | ↗ |
| 2025-10-15 | Kim Christopher | Director / Officer | A-Award | A | Stock Option (right to buy) | 3,000 | 1.92 | 5.8K | 3,000 | D | ↗ |
| 2025-10-15 | Emerson Erik C. | Director / Officer | A-Award | A | Stock Option (right to buy) | 215,000 | 1.92 | 412.8K | 215,000 | D | ↗ |
| 2024-05-12 | Inscobee Inc. | 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
1.26M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Erik C. Emerson | President | 2M | male |
| Christopher Kim | Chief Medical Officer | 625.0K | — |
| Youngjik Cho | Chief Executive Officer & Director | 300.0K | male |
| Erick J. Frim | Chief Financial Officer | 20.3K | male |
| Amardeep Singh | Chief Technology Officer | — | male |
| Vinod Menon | Founder, CEO & Director | — | — |
| Captain Sandeep Yadav | Chief Operating Officer | — | — |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for APUS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
